SEATTLE, Oct. 7, 2025 /PRNewswire/ —
A proposed class action settlement was reached in the lawsuit, Bartz v. Anthropic PBC, which claimed that Anthropic infringed copyrights by downloading allegedly pirated datasets containing copyrighted books. Anthropic denies the allegations.
Authors, publishers, and copyright owners may be Class Members and benefit from the Settlement if they own the copyright of a work included in the LibGen or PiLiMi datasets downloaded by Anthropic.
More details and a searchable database of all books included in the settlement are available at www.AnthropicCopyrightSettlement.com.
Class Members have the following options:
The Court scheduled a hearing for April 23, 2026, at 12:00 PT at the San Francisco Federal Courthouse, 450 Golden Gate Ave., Courtroom 12 – 19th Floor, to consider whether to approve the Settlement. The Court will also consider Class Counsel’s request for attorneys’ fees of up to 25% of the Settlement Fund, reimbursement for other costs and expenses, and service payments of up to $50,000 to each Class Representative, as well as any objections.
Contact Information:
|
Visit: |
|
|
Email: |
|
|
Call: |
1-877-206-2314 |
|
Write: |
|
|
c/o JND Legal Administration |
|
|
P.O. Box 91204 |
|
|
Seattle, WA 98111 |
|
Complete copies of the pleadings, orders and other publicly filed documents in the lawsuit may also be accessed for a fee through the Court’s Public Access to Court Electronic Records (PACER) system at https://ecf.cand.uscourts.gov.
PLEASE DO NOT CONTACT THE COURT REGARDING THIS NOTICE.
View original content:https://www.prnewswire.co.uk/news-releases/authors-publishers-and-copyright-owners-may-benefit-from-a-1-5-billion-class-action-settlement-302576041.html
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…
SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…